Study Summary
This trial is testing if a new way of delivering cancer-fighting cells to people with brain tumors is safe. Participants will get 6 doses given over 8 weeks.
- Diffuse Midline Glioma, H3 K27M-Mutant
- Ependymoma
- Brain Tumor
- Glioblastoma
- Medulloblastoma
- Brain Tumors
- Atypical Teratoid/Rhabdoid Tumor
Treatment Effectiveness
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: Eight (8) weeks after the first B7-H3-CAR T-cell infusion or 7 days after the sixth B7-H3-CAR T cell infusion, whichever is longer
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Arm A (relapsed/refractory CNS tumors)
1 of 2
Arm B (brainstem high-grade neoplasms)
1 of 2
Experimental Treatment
36 Total Participants · 2 Treatment Groups
Primary Treatment: Arm A (relapsed/refractory CNS tumors) · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age < 65 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How precarious is Arm A (relapsed/refractory CNS tumors) for the participants?
"Though limited efficacy and safety data is available, our team at Power assessed Arm A's (relapsed/refractory CNS tumors) security to be a 1 on the 3-point scale." - Anonymous Online Contributor
Are any openings available for patients to join this experiment?
"Unfortunately, this particular clinical trial is not actively looking for participants as of now. The most recent edit on the study's page was made on April 18th 2023. However, 860 other trials are currently recruiting patients for their studies." - Anonymous Online Contributor